Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12364132 | 0.94 | — | — | |
| SCHEMBL10147792 | 0.92 | CA1 (0.33) | — | |
| SCHEMBL9944453 | 0.88 | — | — | |
| SCHEMBL2100610 | 0.77 | — | — | |
| SCHEMBL14667211 | 0.77 | CNR2 (0.38) | — | |
| SCHEMBL19293984 | 0.75 | HTR2A (0.36) | — | |
| SCHEMBL14227526 | 0.74 | — | — | |
| SCHEMBL9611069 | 0.74 | — | — | |
| SCHEMBL3056682 | 0.73 | — | — | |
| SCHEMBL12332410 | 0.72 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-8106035-B2 | 25-SO2-substituted analogs of 1μ,25-dihydroxyvitamin D3 | CYTOCHROMA INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-8106035-B2 | 25-SO2-substituted analogs of 1μ,25-dihydroxyvitamin D3 | CYTOCHROMA INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-8106035-B2 | 25-SO2-substituted analogs of 1μ,25-dihydroxyvitamin D3 | CYTOCHROMA INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20040224930-A1 | 25-SO2-Substituted analogs of 1mu,25-dihydroxyvitamin D3 | Opko IP Holdings II, Inc. (KY) | 2004-11-11 | — | — | US | disclosed |
| WO-2004054968-A2 | 25-SO2-SUBSTITUTED ANALOGS OF 1ALPHA, 25-DIHYDROXYVITAMIN D3 (CALCITRIOL) | JOHNS HOPKINS UNIVERSITY (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ACHE 3069/4885 |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | ACHE 4508/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | ACHE 4695/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ACHE 3069/4885 |
| US-20040224930-A1 | 25-SO2-Substituted analogs of 1mu,25-dihydroxyvitamin D3 | CYP24A1, CYP27B1, CYP2R1 | ACHE 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.